Búsqueda | Biblioteca Virtual en Salud

1.

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

Ledford, Dennis; Busse, William; Trzaskoma, Benjamin; Omachi, Theodore A; Rosén, Karin; Chipps, Bradley E; Luskin, Allan T; Solari, Paul G.

J Allergy Clin Immunol ; 140(1): 162-169.e2, 2017 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-27826098

2.

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

Chipps, Bradley E; Zeiger, Robert S; Luskin, Allan T; Busse, William W; Trzaskoma, Benjamin L; Antonova, Evgeniya N; Pazwash, Hooman; Limb, Susan L; Solari, Paul G; Griffin, Noelle M; Casale, Thomas B.

Ann Allergy Asthma Immunol ; 119(6): 524-532.e2, 2017 12.

Artículo en Inglés | MEDLINE | ID: mdl-29054589

3.

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

Luskin, Allan T; Chipps, Bradley E; Casale, Thomas B; Griffin, Noelle M.

Ann Allergy Asthma Immunol ; 120(5): 549-550, 2018 05.

Artículo en Inglés | MEDLINE | ID: mdl-29421314

4.

The reality of adherence to rhinitis treatment: identifying and overcoming the barriers.

Bukstein, Don; Luskin, Allan T; Farrar, Judith Rosen.

Allergy Asthma Proc ; 32(4): 265-71, 2011.

Artículo en Inglés | MEDLINE | ID: mdl-21781402

5.

Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma.

Bukstein, Don; Luskin, Allan T; Brooks, Elizabeth A.

Allergy Asthma Proc ; 32(3): 185-92, 2011.

Artículo en Inglés | MEDLINE | ID: mdl-21477457

6.

Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paper.

Luskin, Allan T; Blaiss, Michael S; Farrar, Judith R; Settipane, Russell; Hayden, Mary Lou; Stoloff, Stuart; Chadwick, Stephen J; Derebery, M Jennifer; Ettari, Mary P; Luskin, Susan; Naclerio, Robert.

Allergy Asthma Proc ; 32(2): 168-77, 2011.

Artículo en Inglés | MEDLINE | ID: mdl-21352638

7.

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.

Casale, Thomas B; Luskin, Allan T; Busse, William; Zeiger, Robert S; Trzaskoma, Benjamin; Yang, Ming; Griffin, Noelle M; Chipps, Bradley E.

J Allergy Clin Immunol Pract ; 7(1): 156-164.e1, 2019 01.

Artículo en Inglés | MEDLINE | ID: mdl-29800752

8.

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life.

Chipps, Bradley E; Haselkorn, Tmirah; Rosén, Karin; Mink, David R; Trzaskoma, Benjamin L; Luskin, Allan T.

J Allergy Clin Immunol Pract ; 6(1): 169-176.e2, 2018.

Artículo en Inglés | MEDLINE | ID: mdl-28803186

9.

Pharmacoeconomics of Biologic Therapy.

Bukstein, Don A; Luskin, Allan T.

Immunol Allergy Clin North Am ; 37(2): 413-430, 2017 05.

Artículo en Inglés | MEDLINE | ID: mdl-28366485

10.

Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.

Luskin, Allan T; Antonova, Evgeniya N; Broder, Michael S; Chang, Eunice; Raimundo, Karina; Solari, Paul G.

J Manag Care Spec Pharm ; 23(11): 1117-1124, 2017 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-29083971

11.

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis.

Luskin, Allan T; Antonova, Evgeniya N; Broder, Michael S; Chang, Eunice Y; Omachi, Theodore A; Ledford, Dennis K.

Clinicoecon Outcomes Res ; 8: 641-648, 2016.

Artículo en Inglés | MEDLINE | ID: mdl-27822075

12.

Anaphylaxis and Anaphylactoid Reactions: Diagnosis and Management.

Luskin, Allan T.; Luskin, Susan S..

Am J Ther ; 3(7): 515-520, 1996 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-11862283

13.

Clinical and economic effects of suboptimally controlled asthma.

Bootman, J Lyle; Crown, William H; Luskin, Allan T.

Manag Care Interface ; 17(1): 31-6, 2004 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-15035598

14.

Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma.

Luskin, Allan T; Chipps, Bradley E; Rasouliyan, Lawrence; Miller, Dave P; Haselkorn, Tmirah; Dorenbaum, Alejandro.

J Allergy Clin Immunol Pract ; 2(5): 544-52.e1-2, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-25213047

15.

Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol.

Markson, Leona E; Bukstein, Don A A; Luskin, Allan T.

J Manag Care Pharm ; 12(6): 486-7; author reply 487-9, 2006.

Artículo en Inglés | MEDLINE | ID: mdl-16925457

16.

Achieving asthma control: the need for risk assessment.

Luskin, Allan T.

Manag Care ; 14(8 Suppl): 12-5; discussion 25-7, 2005 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-16167482

17.

The economic burden associated with prior authorizations in an allergist office.

Bukstein, Don A; Cherayil, Greeta A; Gepner, Adam D; Luskin, Allan T; Kooistra, J Brent; Olson, Reid M.

Allergy Asthma Proc ; 27(2): 119-22, 2006.

Artículo en Inglés | MEDLINE | ID: mdl-16724629

18.

What the asthma end points we know and love do and do not tell us.

Luskin, Allan T.

J Allergy Clin Immunol ; 115(4 Suppl): S539-45, 2005 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-15806037

19.

Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL).

Luskin, Allan T; Kosinski, Mark; Bresnahan, Brian W; Ashby, Mark; Wong, Dennis A.

J Asthma ; 42(10): 823-7, 2005 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-16393718

20.

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma.

Bukstein, Don A; Luskin, Allan T; Bernstein, Avi.

Ann Allergy Asthma Immunol ; 90(5): 543-9, 2003 May.

Artículo en Inglés | MEDLINE | ID: mdl-12775136

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

The reality of adherence to rhinitis treatment: identifying and overcoming the barriers.

Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma.

Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paper.

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life.

Pharmacoeconomics of Biologic Therapy.

Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis.

Anaphylaxis and Anaphylactoid Reactions: Diagnosis and Management.

Clinical and economic effects of suboptimally controlled asthma.

Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma.

Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol.

Achieving asthma control: the need for risk assessment.

The economic burden associated with prior authorizations in an allergist office.

What the asthma end points we know and love do and do not tell us.

Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL).

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma.